IRIS
BATTIPAGLIA, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.142
NA - Nord America 1.246
EU - Europa 1.068
SA - Sud America 297
AF - Africa 68
OC - Oceania 3
Totale 4.824
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.197
SG - Singapore 1.057
RU - Federazione Russa 581
CN - Cina 374
VN - Vietnam 252
BR - Brasile 225
HK - Hong Kong 188
IT - Italia 174
FR - Francia 87
JP - Giappone 63
IN - India 54
NL - Olanda 54
DE - Germania 49
BD - Bangladesh 40
KR - Corea 35
AR - Argentina 30
GB - Regno Unito 30
CA - Canada 22
CI - Costa d'Avorio 21
PL - Polonia 18
IE - Irlanda 16
IQ - Iraq 14
MX - Messico 14
ZA - Sudafrica 14
EC - Ecuador 12
FI - Finlandia 11
AT - Austria 10
CO - Colombia 10
BE - Belgio 7
ID - Indonesia 7
PK - Pakistan 7
DZ - Algeria 6
PY - Paraguay 6
TH - Thailandia 6
UA - Ucraina 6
CL - Cile 5
NP - Nepal 5
TR - Turchia 5
BO - Bolivia 4
ES - Italia 4
JO - Giordania 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
EG - Egitto 3
KW - Kuwait 3
LT - Lituania 3
TW - Taiwan 3
UZ - Uzbekistan 3
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
LU - Lussemburgo 2
LV - Lettonia 2
MA - Marocco 2
MY - Malesia 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
SE - Svezia 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
CG - Congo 1
CM - Camerun 1
CR - Costa Rica 1
CV - Capo Verde 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
HR - Croazia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MG - Madagascar 1
ML - Mali 1
MQ - Martinica 1
NG - Nigeria 1
PS - Palestinian Territory 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SO - Somalia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UG - Uganda 1
VE - Venezuela 1
Totale 4.820
Salva come PNG Salva come JPEG
Città #
Singapore 499
San Jose 213
Hong Kong 183
Moscow 135
Santa Clara 132
Hefei 120
Ashburn 96
Beijing 91
Ho Chi Minh City 84
Lauterbourg 63
Tokyo 59
Amsterdam 46
The Dalles 46
Hanoi 45
Los Angeles 42
Dallas 40
Boston 33
Lawrence 33
Naples 31
Buffalo 27
Redondo Beach 27
Seoul 26
Des Moines 24
Kochi 24
New York 23
Millbury 21
São Paulo 21
Council Bluffs 18
Milan 16
Da Nang 15
Haiphong 15
Nuremberg 15
Chandler 14
Dublin 14
Frankfurt am Main 12
Gdansk 12
Mumbai 10
Wilmington 10
Rome 9
Johannesburg 8
London 8
Munich 8
Rio de Janeiro 8
Seattle 8
Toronto 8
Denver 7
Woodbridge 7
Biên Hòa 6
Chicago 6
Helsinki 6
Mexico City 6
Orem 6
Arezzo 5
Bologna 5
Can Tho 5
Chennai 5
Houston 5
Roubaix 5
Washington 5
Wuhan 5
Asunción 4
Bangkok 4
Bari 4
Curitiba 4
Fairfield 4
Falkenstein 4
Florianópolis 4
Kathmandu 4
La Paz 4
Miami 4
Phoenix 4
Porto Alegre 4
Ravenna 4
Ribeirão Preto 4
Vienna 4
Amman 3
Atlanta 3
Baghdad 3
Bexley 3
Brasília 3
Brussels 3
Cairo 3
Camponogara 3
Cape Town 3
Catania 3
Cologno Monzese 3
Cotia 3
Dhaka 3
Düsseldorf 3
Genoa 3
Guarulhos 3
Guayaquil 3
Hải Dương 3
Jacksonville 3
Lahore 3
Lappeenranta 3
Manchester 3
Medellín 3
Modena 3
Nanjing 3
Totale 2.611
Salva come PNG Salva come JPEG
Nome #
JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. 143
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience 134
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation 113
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 108
Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML). 106
Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study 104
Hematopoietic cell transplant nurse coordinators’ perceptions of related donor care: a European survey from the EBMT Nurses Group 99
Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes 98
Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria 97
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update 93
Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center experience 92
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: A report of the EBMT Acute Leukemia Working Party 91
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies 91
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation 89
CD34+-selected stem cell “Boost” for poor graft function after allogeneic hematopoietic stem cell transplantation 89
Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting 89
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation 88
Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation 88
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients 86
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia 86
Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation 86
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? 85
Managing haemorragic and thromboembolic risk in patients with acquired haemophilia 84
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT 84
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT 77
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT 73
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 70
Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation 70
Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation 65
Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors 64
The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT) 64
Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia 63
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: An ALWP-EBMT study 63
Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study 60
Medication adherence among allogeneic hematopoietic stem cell transplant recipients: A pilot single-center study 59
Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT 59
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT 58
Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT 57
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 57
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 57
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 57
Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT 56
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia 56
Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients 56
Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 55
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee 55
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: A study from the acute leukemia working party of the european society for blood and marrow transplantation 53
Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse 53
Transmission of Legionnaires' Disease through Toilet Flushing 53
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT 52
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 51
Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation 51
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT 51
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 50
Inhibition of FLT3 in AML: A focus on sorafenib 50
Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma 46
Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation 45
Urgent need: evidence-based use of donor lymphocyte infusions – Authors' reply 44
Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT 44
High-dose post-transplant cyclophosphamide impairs γδ T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft 44
Congress report: European Group for Blood and Marrow Transplantation (EBMT) 2015 44
New strategies of allogeneic hematopoietic stem cell transplantation with the use of haploidentical donors 43
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 42
Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study 42
Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient 42
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT 39
Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT 38
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study 37
Real‐world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study 34
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) 33
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 31
Erythroid‐stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 29
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT 28
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis 24
Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in complete remission: a matched-pair analysis on behalf of the Acute Leukemia Working Party of the EBMT 23
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT 18
Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation 18
Totale 4.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 1 4
2021/202297 0 0 0 0 0 0 0 6 9 1 4 77
2022/2023157 34 0 0 1 3 12 3 18 20 43 17 6
2023/2024240 8 32 21 9 58 10 10 31 1 3 34 23
2024/20251.493 75 111 0 7 54 69 182 82 129 159 504 121
2025/20262.858 256 305 390 254 478 105 204 279 327 143 117 0
Totale 4.926